Brind.

Merck KGaA, Gilead Sciences, and Pfizer are competing in the fragmented HIV drug market.

1 report, 1 independent Updated Aug 5

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Merck KGaA Gilead Sciences Pfizer

Keep exploring

The entities involved

Merck KGaA
German multinational science and technology company
- Keytruda received FDA approval for cancer treatment, involving Merck KGaA.Mon 17:33
- Merck KGaA acquired Schering-Plough in 2009.Sun 17:36
Gilead Sciences
American company
- FDA approved lenacapavir (Yeztugo) on August 18, 2025, solidifying the HIV portfolio for Gilead Sciences.Mon 18:04
- Dean Hakanson led U.S. Medical Affairs for the remdesivir launch and served in senior leadership positions at major pharmaceutical companies.Mon 17:32
Pfizer
American multinational pharmaceutical and biotechnology corporation
- Verizon's Frontier deal increased debt, while Kraft Heinz and Pfizer stock traded on Nasdaq.Mon 13:09
- In Alberta, Moderna doses are publicly funded while Pfizer shots are sought by private payers.Sun 19:50

Related events

Merck KGaA and ABVC BioPharma are competing for investment as healthcare companies.Oct 16

Coverage

Newest first; wire copies grouped

Aug 5biopharmadive.com